關鍵數據
3.610今開
3.820最高
100.00成交量
0.09本益比TTM
虧損本益比動
--股利TTM
0.00%換手率
3.570昨收
3.600最低
370.00成交額
虧損本益比靜
-0.50市淨率
0.00%股息率 TTM
-41.17%ROA
10.47052週最高
0.02量比
-47.58M淨利潤
4.05M總股本
40.4711每股盈餘TTM
1.03Beta
--ROE
3.50052週最低
16.81%振幅
-81.45%毛利率
14.90M總市值
0.05回報/風險
3.50%風險率

即將為您帶來更多新聞,敬請期待。 。 。
分析師評級
買入評級
38.500目標均價
+742.45%漲幅空間
FibroGen Ord Shs 最新財報電話會記錄
KYNB 2026 年第二季法說會:9,570 萬美元流動資金與第四季臨床催化劑
KYNB 的 2026 財年第二季法說會內容涵蓋 9,570 萬美元的流動資金、可支持營運至 2028 年的資金續航力,以及 FG-3246 和 roxadustat 在第四季的催化因素。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
FibroGen Ord Shs 簡介
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
持股情況
| 持股股東 | 佔比 |
|---|
| Armistice Capital LLC | 9.88% |
|---|
| Vanguard Capital Management, LLC | 3.87% |
|---|
| Acadian Asset Management LLC | 2.61% |
|---|
| BlackRock Institutional Trust Company, N.A. | 2.08% |
|---|
| 股東類型 | 佔比 |
|---|
| Hedge Fund | 13.42% |
|---|
| Investment Advisor | 9.24% |
|---|
| Investment Advisor/Hedge Fund | 5.64% |
|---|
| Individual Investor | 1.96% |
|---|
常見問題
FibroGen Ord Shs(KYNB)的當前股價是多少?
FibroGen Ord Shs(KYNB)的當前股價是 3.68。
FibroGen Ord Shs 的股票代碼是什麼?
FibroGen Ord Shs的股票代碼是KYNB。
FibroGen Ord Shs股票的52週最高點是多少?
FibroGen Ord Shs股票的52週最高點是10.47。
FibroGen Ord Shs股票的52週最低點是多少?
FibroGen Ord Shs股票的52週最低點是3.50。
FibroGen Ord Shs的市值是14.90M。
現在FibroGen Ord Shs(KYNB)的股票是買入、持有還是賣出?
根據分析師評級,FibroGen Ord Shs(KYNB)的總體評級為買入,目標價格為38.50。
FibroGen Ord Shs(KYNB)股票的每股收益(EPS TTM)是多少
FibroGen Ord Shs(KYNB)股票的每股收益(EPS TTM)是40.47。